Suzanne McGurn
President and Chief Executive Officer, Canada's Drug Agency
Sessions >
- Official Opening
- Opening Plenary: Introducing Canada’s Drug Agency
Sudha Kutty
Executive Vice-President, Evidence, Products, and Services, Canada's Drug Agency
Sessions >
- Early Morning Session 1: Moving Beyond Opening a Window to Creating a Door
- Panel Session 1: Innovation in the Pharmaceutical Ecosystem
- Panel Session 9: Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
- Panel Session 14: Improving Patient Safety and Outcomes: A Vision for a pan-Canadian Coordinated Approach to Appropriate Use
Dr. Nicole Mittmann
Chief Scientist and Vice President, Scientific Evidence, Methodologies and Resources, Canada's Drug Agency
Sessions >
- Special Session 4: Canada’s Drug Agency Initiatives in Drugs for Rare Diseases
- Early Morning Session 1: Moving Beyond Opening a Window to Creating a Door
- Panel Session 12: Advancing Patient Engagement and Impact in Canada's Drug Agency Deliberative Process: A Multistakeholder Collaboration
- Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Dr. Kwadwo Kyeremanteng
Department Head of Critical Care, The Ottawa Hospital
Sessions >
- Symposium Dinner
Kate Harback
CEO and Executive Director, Institute of Health Economics
Sessions >
- Early Morning Session 2: Operationalizing Outcomes-Based Agreements in Canada
Mina Tadrous
Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
Sessions >
- Early Morning Session 3: The Growing Problem of Drug Shortages: Understanding Their Impact on Research, Patients, and Health Care Systems
Guillaume Couillard
Executive Director, Patented Medicine Prices Review Board
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency
Patrick Dicerni
Assistant Deputy Minister Health Programs and Delivery Division and Executive Office, Ontario Public Drug Programs, Ontario Ministry of Health and Long-Term Care
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency
Daniel Ollendorf
Chief Scientific Officer and Director of HTA Methods Development, ICER
Sessions >
- Early Morning Session 8: What’s New in US HTA? A Snapshot of ICER’s Value Assessment Framework Update
- Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Marina Richardson
Associate Director, HTA Methods and Health Economics, ICER
Sessions >
- Early Morning Session 8: What’s New in US HTA? A Snapshot of ICER’s Value Assessment Framework Update
- Panel Session 13: Closing the Gap Or Widening The Divide: Do We Need a Framework for Truly Embedding Equity in Health Technology Assessment (HTA)?
Dr. Nick Crabb
Chief Scientific Officer, National Institute for Health and Care Excellence (NICE)
Sessions >
- Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Pascale Lehoux
Vice-Présidente Scientifique, INESSS
Sessions >
- Oral Presentations 5: An Actionable and Legible Toolbox for the Appraisal of Health Care Innovations Developed Through Provincial Stakeholder Collaboration
- Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Shawn Paron
Chief Operating Officer, Alzheimer Society of Ontario
Sessions >
- Early Morning Session 5: Real-World Evidence (RWE): Empowering Patient Advocacy Groups to Co-Design Registries That Fill a Data Gap for Their Community
Bonnie Macfarlane
Associate Director, Health Technology Assessment, Submissions and Analytics, Janssen Inc
Sessions >
- Panel session 12: Advancing Patient Engagement and Impact in Canada's Drug Agency Deliberative Process: A Multistakeholder Collaboration
Don Husereau
Adjunct Professor, SEPH, University of Ottawa
Sessions >
- Workshop 4: An Introduction to Health Technology Assessment
- Panel Session 4: Breaking Barriers: Tackling Challenges in Mental Health Drug Health Technology Assessments
Beth Kidd
Executive Director, Health Coalition of Alberta
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency
- Panel Session 9: Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
Bettina Hamelin
President, Innovative Medicines Canada
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency
Daniel MacDonald
Director General, Office of Pharmaceutical Management Strategies, Strategic Policy Branch, Health Canada
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency
Dr. Avram Denburg
Staff Oncologist and Clinician-Scientist in the Division of Haematology/Oncology, SickKids
Sessions >
- Workshop 3: Unlocking Ethics in HTA: Exploring Practice and Impact
Dr. Jim Silvius
Chair, Canadian Drug Expert Committee (CDEC)
Sessions >
- Panel Session 14: Improving Patient Safety and Outcomes: A Vision for a pan-Canadian Coordinated Approach to Appropriate Use
Dr. Muhammad Mamdani
Vice President - Data Science and Advanced Analytics, Unity Health Toronto
Sessions >
- Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Dominic Tan
Acting CEO, pan-Canadian Pharmaceutical Alliance
Sessions >
- Opening Plenary: Introducing Canada’s Drug Agency